143 related articles for article (PubMed ID: 14574916)
1. [Toxicities associated with chemotherapy in colorectal cancer].
Ura T; Shirao K
Nihon Rinsho; 2003 Sep; 61 Suppl 7():374-8. PubMed ID: 14574916
[No Abstract] [Full Text] [Related]
2. Investigation into the usefulness and adverse events of CDDP, 5-fU and dl-leucovorin (PFL-therapy) for advanced colorectal cancer.
Okabe S; Ishikawa T; Tanami H; Kuwabara H; Fukahara T; Udagawa M; Ootsukasa S; Arai T; Maruyama S; Murase N; Yamashita H; Iwai T
J Med Dent Sci; 2002 Jun; 49(2):77-84. PubMed ID: 12627817
[TBL] [Abstract][Full Text] [Related]
3. Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database.
Wagner AD; Grothey A; Andre T; Dixon JG; Wolmark N; Haller DG; Allegra CJ; de Gramont A; VanCutsem E; Alberts SR; George TJ; O'Connell MJ; Twelves C; Taieb J; Saltz LB; Blanke CD; Francini E; Kerr R; Yothers G; Seitz JF; Marsoni S; Goldberg RM; Shi Q
J Natl Cancer Inst; 2021 Apr; 113(4):400-407. PubMed ID: 32835356
[TBL] [Abstract][Full Text] [Related]
4. Current status of capecitabine in the treatment of colorectal cancer.
Rothenberg ML
Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):16-22. PubMed ID: 12520635
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L
Oncology; 2004; 66(5):371-8. PubMed ID: 15331924
[TBL] [Abstract][Full Text] [Related]
6. Moving beyond fluorouracil for colorectal cancer.
Mayer RJ
N Engl J Med; 2000 Sep; 343(13):963-4. PubMed ID: 11006373
[No Abstract] [Full Text] [Related]
7. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
[TBL] [Abstract][Full Text] [Related]
8. Recommendation for irinotecan, 5-fluorouracil, and leucovorin as first-line therapy for colorectal cancer.
Fisher MD
Clin Colorectal Cancer; 2001 Aug; 1(2):82-4. PubMed ID: 12445364
[No Abstract] [Full Text] [Related]
9. [Irinotecan plus fluorouracil and leucovorin for advanced colorectal cancer].
Motomura S
Nihon Rinsho; 2003 Sep; 61 Suppl 7():360-3. PubMed ID: 14574913
[No Abstract] [Full Text] [Related]
10. The Roswell Park Memorial Institute and Gastrointestinal Tumor Study Group phase III experience with the modulation of 5-fluorouracil by leucovorin in metastatic colorectal adenocarcinoma.
Petrelli NJ; Rustum YM; Bruckner H; Stablein D
Adv Exp Med Biol; 1988; 244():143-55. PubMed ID: 3073651
[No Abstract] [Full Text] [Related]
11. [5-fluorouracil and leucovorin therapy for advanced colorectal cancer].
Shimoyama S; Kondo K; Kataoka M
Nihon Rinsho; 2003 Sep; 61 Suppl 7():356-9. PubMed ID: 14574912
[No Abstract] [Full Text] [Related]
12. Outpatient therapy with irinotecan and low-dose cisplatin for metastatic colorectal cancer resistant to 5-fluorouracil.
Shimada S; Yagi Y; Shiomori K; Kuramoto M; Aoki N; Ogawa M
Oncol Rep; 2002; 9(4):783-7. PubMed ID: 12066209
[TBL] [Abstract][Full Text] [Related]
13. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer.
Ledermann JA; Leonard P; Seymour M
N Engl J Med; 2001 Jul; 345(2):145-6. PubMed ID: 11450667
[No Abstract] [Full Text] [Related]
14. Capecitabine and irinotecan as first-line treatment of advanced colorectal cancer.
Punt CJ; Koopman M
J Clin Oncol; 2008 Apr; 26(11):1907-8; author reply 1908-9. PubMed ID: 18398161
[No Abstract] [Full Text] [Related]
15. Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity?
Soveri LM; Hermunen K; de Gramont A; Poussa T; Quinaux E; Bono P; André T; Österlund P
Eur J Cancer; 2014 Nov; 50(17):2966-74. PubMed ID: 25266443
[TBL] [Abstract][Full Text] [Related]
16. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
Erlichman C; Goldberg RM; O'Connell MJ
N Engl J Med; 2001 Jan; 344(4):305; author reply 306-7. PubMed ID: 11191661
[No Abstract] [Full Text] [Related]
17. Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials.
Bin Q; Li J; Liao C; Cao Y; Gao F
Colorectal Dis; 2011 Aug; 13(8):837-45. PubMed ID: 20050863
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of FOLFIRI regimen in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin.
Bao HY; Fang WJ; Zhang XC; Shi GM; Huang S; Yu LF; Chen J; Mou HB; Deng J; Shen P; Xu N
Cancer Chemother Pharmacol; 2011 Jan; 67(1):147-52. PubMed ID: 20221830
[TBL] [Abstract][Full Text] [Related]
19. [Irinotecan plus fluorouracil and folinic acid in metastatic colorectal cancer].
Krieger G
Strahlenther Onkol; 2001 Jun; 177(6):316-8. PubMed ID: 11446323
[No Abstract] [Full Text] [Related]
20. Oxaliplatin plus hydroxycamptothecine versus oxaliplatin plus 5-fluorouracil and leucovorin in treatment of advanced colorectal cancer.
Yao Y; Sun YJ; Zhao H; Guo YW; Lin F; Cai X; Tang XC; Tang LN; Zhang W
Chin Med J (Engl); 2006 Nov; 119(21):1829-33. PubMed ID: 17097039
[No Abstract] [Full Text] [Related]
[Next] [New Search]
